I never claimed its impossible for a cancer treatment drug to be granted approval after a phase 2 drug, its only very rare. In the case of Gleevec there was no alternative and the FDA approved the drug with record speed for oral therapy for the treatment of patients with chronic myeloid leukemia (CML).
Like I said Im certain DCVAX will NOT be granted approval for other solid tumor cancer indications in other organs for most all of these indications already have treatments approved after phase 3 trials. The companies behind these drugs, after having invested hundreds of millions in phase 3, will have a field day suing the FDA over granting DCVAX approval after P2 and competing with their investment without a Phase 3 trial and thus without proving DCVAX is a better or equal treatment,
Take for example Gilead acquiring Immunomedics for solid tumors for 21 billion. Do you think Gilead is just going to accept a swift and small Phase 2 DCVAX trial for solid tumor breast cancer to compete with their 21 billion investment? Of course not.
So NWBO diehard longs fantasy.
Market Data 
Markets 
AI
